m6A-centered Crosstalk Information
Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
| Crosstalk ID |
M6ACROT00066
|
[1] | |||
.png)
.png)
 : modification sites
Indirect
Enhancement
m6A modification
ARHGAP5
ARHGAP5
YTHDF1
 : m6A sites
|
|||||
| m6A Modification: | |||||
|---|---|---|---|---|---|
| m6A Regulator | YTH domain-containing family protein 1 (YTHDF1) | READER | |||
| m6A Target | Rho GTPase activating protein 5 (ARHGAP5) | ||||
| Epigenetic Regulation that have Cross-talk with This m6A Modification: | |||||
| Epigenetic Regulation Type | RNA modification (RNAMod) >> Adenosine-to-Inosine editing (A-to-I) | ||||
| Epigenetic Regulator | Interferon-inducible protein 4 (ADAR1) | WRITER | View Details | ||
| Regulated Target | Methyltransferase-like protein 3 (METTL3) | View Details | |||
| Crosstalk Relationship | A-to-I → m6A | Enhancement | |||
| Crosstalk Mechanism | RNA modification indirectly impacts m6A modification through downstream signaling pathways | ||||
| Crosstalk Summary | overexpression and knockdown of ADAR1 respectively increased and decreased the expression levels of Methyltransferase-like protein 3 (METTL3) and Rho GTPase activating protein 5 (ARHGAP5) protein in breast cancer. Study demonstrate that ADAR1 promotes the proliferation, migration and invasion of breast cancer cells through the METTL3/ARHGAP5/YTHDF1 axis and establish that METTL3 is one of the main targets of ADAR1 controlling biological functions. | ||||
| Responsed Disease | Breast cancer | ICD-11: 2C60 | |||
| Cell Process | Cell proliferation | ||||
| Cell migration | |||||
| Cell invasion | |||||
In-vitro Model |
MDA-MB-231 | Breast adenocarcinoma | Homo sapiens | CVCL_0062 | |
| T-47D | Invasive breast carcinoma | Homo sapiens | CVCL_0553 | ||
| In-vivo Model | Roughly 1 × 107 of MCF-7 or MDA-MB-231 cells stably transfected with ADAR1 sgRNA or Ctrl sgRNA (as described above) were injected subcutaneously into the thighs of the female athymic nude mice (5 weeks old, 17-18 g, three mice per group). Tumor growth was measured by measuring the width (W) and length (L) with calipers, and the volume (V) of the tumor was figured using the criterion V = (W2 × L)/2. At 43 days after injection, the mice were euthanized and tumors were removed and weighed. The tumor samples were further analyzed with IHC and Western blot assay. The animal studies were performed according to the institutional ethics guidelines for animal experiments and approved by the Chongqing Medical University Animal Care and Use Committee. | ||||
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
| 2C60: Breast cancer | 2 Compound(s) Regulating the Disease | Click to Show/Hide the Full List | ||
 Compound Name |
Entrectinib | Approved | [2] | |
|---|---|---|---|---|
| Synonyms |
1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK
Click to Show/Hide
|
|||
| External Link | ||||
| Compound Name |
Everolimus | Approved | [3] | |
| External Link | ||||
References